Hot Topics in Pharmacology

Coronavrius Information

We are currently collating information related to SARS-CoV-2 and COVID-19 at a dedicated coronavirus information page. This contains details of ligands and targets relevant to COVID-19 and links to useful resources and publications.

Recent publications of interest recommended by NC-IUPHAR

2023: May | Apr | Mar | Feb | Jan
2022: Dec | Nov | Oct | Sep | Aug | Jul | Jun

    May 2023


  • Advances in Malaria Pharmacology and the online Guide to MALARIA PHARMACOLOGY: IUPHAR Review X.
     Armstrong JF, Campo B, Alexander SPH, Arendse LB, Cheng X, Davenport AP, Faccenda E, Fidock DA, Godinez-Macias KP, Harding SD et al.. Advances in Malaria Pharmacology and the online Guide to MALARIA PHARMACOLOGY: IUPHAR Review X. (2023)  Br J Pharmacol, [Epub ahead of print]. [PMID:37197802]
  • The VGNC: expanding standardized vertebrate gene nomenclature.
     Jones TEM, Yates B, Braschi B, Gray K, Tweedie S, Seal RL, Bruford EA. The VGNC: expanding standardized vertebrate gene nomenclature. (2023)  Genome Biol, 24 (1): 115. [PMID:37173739]
  • A small-molecule PI3Kα activator for cardioprotection and neuroregeneration.
     Gong GQ, Bilanges B, Allsop B, Masson GR, Roberton V, Askwith T, Oxenford S, Madsen RR, Conduit SE, Bellini D et al.. A small-molecule PI3Kα activator for cardioprotection and neuroregeneration. (2023)  Nature, [Epub ahead of print]. [PMID:37225977]
  • Bilirubin gates the TRPM2 channel as a direct agonist to exacerbate ischemic brain damage.
     Liu HW, Gong LN, Lai K, Yu XF, Liu ZQ, Li MX, Yin XL, Liang M, Shi HS, Jiang LH et al.. Bilirubin gates the TRPM2 channel as a direct agonist to exacerbate ischemic brain damage. (2023)  Neuron, 111 (10): 1609-1625.e6. [PMID:36921602]
  • FDA approves first-in-class NK3 receptor antagonist for hot flushes.
     Mullard A. FDA approves first-in-class NK3 receptor antagonist for hot flushes. (2023)  Nat Rev Drug Discov, [Epub ahead of print]. [PMID:37208488]
  • Identification and Classification of Papain-like Cysteine Proteinases.
     Ozhelvaci F, Steczkiewicz K. Identification and Classification of Papain-like Cysteine Proteinases. (2023)  J Biol Chem,: 104801 [Epub ahead of print]. [PMID:37164157]

    • April 2023


  • Structural basis for severe pain caused by mutations in the S4-S5 linkers of voltage-gated sodium channel NaV1.7.
     Wisedchaisri G, Gamal El-Din TM, Zheng N, Catterall WA. Structural basis for severe pain caused by mutations in the S4-S5 linkers of voltage-gated sodium channel NaV1.7. (2023)  Proc Natl Acad Sci U S A, 120 (14): e2219624120. [PMID:36996107]
  • Orphan receptor GPR158 serves as a metabotropic glycine receptor: mGlyR.
     Laboute T, Zucca S, Holcomb M, Patil DN, Garza C, Wheatley BA, Roy RN, Forli S, Martemyanov KA. Orphan receptor GPR158 serves as a metabotropic glycine receptor: mGlyR. (2023)  Science, 379 (6639): 1352-1358. [PMID:36996198]
  • ATP-releasing SWELL1 channel in spinal microglia contributes to neuropathic pain.
     Chu J, Yang J, Zhou Y, Chen J, Chen KH, Zhang C, Cheng HY, Koylass N, Liu JO, Guan Y et al.. ATP-releasing SWELL1 channel in spinal microglia contributes to neuropathic pain. (2023)  Sci Adv, 9 (13): eade9931. [PMID:36989353]
  • SVEP1 is an endogenous ligand for the orphan receptor PEAR1.
     Elenbaas JS, Pudupakkam U, Ashworth KJ, Kang CJ, Patel V, Santana K, Jung IH, Lee PC, Burks KH, Amrute JM et al.. SVEP1 is an endogenous ligand for the orphan receptor PEAR1. (2023)  Nat Commun, 14 (1): 850. [PMID:36792666]
  • Structural insights into constitutive activity of 5-HT6 receptor.
     He L, Zhao Q, Qi J, Wang Y, Han W, Chen Z, Cong Y, Wang S. Structural insights into constitutive activity of 5-HT6 receptor. (2023)  Proc Natl Acad Sci U S A, 120 (14): e2209917120. [PMID:36989299]

    • March 2023


  • The evolution of antibiotic resistance is associated with collateral drug phenotypes in Mycobacterium tuberculosis.
     Waller NJE, Cheung CY, Cook GM, McNeil MB. The evolution of antibiotic resistance is associated with collateral drug phenotypes in Mycobacterium tuberculosis. (2023)  Nat Commun, 14 (1): 1517. [PMID:36934122]
  • A broad-spectrum synthetic antibiotic that does not evoke bacterial resistance.
     Heithoff DM, Mahan SP, Barnes V L, Leyn SA, George CX, Zlamal JE, Limwongyut J, Bazan GC, Fried JC, Fitzgibbons LN et al.. A broad-spectrum synthetic antibiotic that does not evoke bacterial resistance. (2023)  EBioMedicine, 89: 104461. [PMID:36801104]
  • A reference cell tree will serve science better than a reference cell atlas
    Domcke S, Shendure J. A reference cell tree will serve science better than a reference cell atlas. (2023)  Cell, 186 (6): 1103-1114. [PMID:36931241]
    Lowe D. Organizing Our Thoughts About Cells - Finally.  In the Pipeline, https://www.science.org/content/blog-post/organizing-our-thoughts-about-cells-finally
  • A community Biased Signaling Atlas.
     Caroli J, Mamyrbekov A, Harpsøe K, Gardizi S, Dörries L, Ghosh E, Hauser AS, Kooistra AJ, Gloriam DE. A community Biased Signaling Atlas. (2023)  Nat Chem Biol, [Epub ahead of print]. [PMID:36973443]
  • Purinergic GPCR-integrin interactions drive pancreatic cancer cell invasion.
     Tomas Bort E, Joseph MD, Wang Q, Carter EP, Roth NJ, Gibson J, Samadi A, Kocher HM, Simoncelli S, McCormick PJ et al.. Purinergic GPCR-integrin interactions drive pancreatic cancer cell invasion. (2023)  Elife, 12 [Epub ahead of print]. [PMID:36942939]
  • Getting the SMILES right: identifying inconsistent chemical identities in the ECHA database, PubChem and the CompTox Chemicals Dashboard.
     Glüge J, McNeill K, Scheringer M. Getting the SMILES right: identifying inconsistent chemical identities in the ECHA database, PubChem and the CompTox Chemicals Dashboard. (2023)  Environ. Sci.: Adv.,. DOI: 10.1039/D2VA00225F
  • Autoregulation of GPCR signalling through the third intracellular loop.
     Sadler F, Ma N, Ritt M, Sharma Y, Vaidehi N, Sivaramakrishnan S. Autoregulation of GPCR signalling through the third intracellular loop. (2023)  Nature, [Epub ahead of print]. [PMID:36890236]
  • Chemistry, structure and function of approved oligonucleotide therapeutics.
     Egli M, Manoharan M. Chemistry, structure and function of approved oligonucleotide therapeutics. (2023)  Nucleic Acids Res, [Epub ahead of print]. [PMID:36881759]
  • Unsaturated bond recognition leads to biased signal in a fatty acid receptor.
     Mao C, Xiao P, Tao XN, Qin J, He QT, Zhang C, Guo SC, Du YQ, Chen LN, Shen DD et al.. Unsaturated bond recognition leads to biased signal in a fatty acid receptor. (2023)  Science,: eadd6220 [Epub ahead of print]. [PMID:36862765]
  • Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation.
     Mead RJ, Shan N, Reiser HJ, Marshall F, Shaw PJ. Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. (2023)  Nat Rev Drug Discov, 22 (3): 185-212. [PMID:36543887]
  • Methods and applications for single-cell and spatial multi-omics.
     Vandereyken K, Sifrim A, Thienpont B, Voet T. Methods and applications for single-cell and spatial multi-omics. (2023)  Nat Rev Genet,: 1-22 [Epub ahead of print]. [PMID:36864178]

    • February 2023


  • Structural basis of efficacy-driven ligand selectivity at GPCRs.
     Powers AS, Pham V, Burger WAC, Thompson G, Laloudakis Y, Sexton PM, Paul SM, Christopoulos A, Thal DM, Felder CC et al.. Structural basis of efficacy-driven ligand selectivity at GPCRs. (2023)  Nat Chem Biol, [Epub ahead of print]. [PMID:36782010]
  • The case for standardizing gene nomenclature in vertebrates
    McCarthy FM, Jones TEM, Kwitek AE, Smith CL, Vize PD, Westerfield M, Bruford EA. The case for standardizing gene nomenclature in vertebrates. (2023)  Nature, 614 (7948): E31-E32. [PMID:36792746]
    VGNC. A Debate About Vertebrate Gene Naming.  https://blog.genenames.org, https://blog.genenames.org/vgnc/2023/2/16/A-Debate-About-Vertebrate-Gene-Naming
  • Uncovering the Heritable Components of Multimorbidities and Disease Trajectories: A Nationwide Cohort Study.
     Westergaard D, Jørgensen FH, Waaben J, Lademann M, Hansen TF, Cremers J, Ostrowsk SRi, Pedersen OBV, Danish Blood Donor Study Genomic Consortium et al.. Uncovering the Heritable Components of Multimorbidities and Disease Trajectories: A Nationwide Cohort Study. (2023)  medRxiv, Preprint. DOI: 10.1101/2023.02.08.23285642
  • Investigating the potential of GalR2 as a drug target for neuropathic pain.
     Rich K, Rehman S, Jerman J, Wilkinson G. Investigating the potential of GalR2 as a drug target for neuropathic pain. (2022)  Neuropeptides, 98: 102311 [Epub ahead of print]. [PMID:36580831]
  • The evolving role of investigative toxicology in the pharmaceutical industry.
     Pognan F, Beilmann M, Boonen HCM, Czich A, Dear G, Hewitt P, Mow T, Oinonen T, Roth A, Steger-Hartmann T et al.. The evolving role of investigative toxicology in the pharmaceutical industry. (2023)  Nat Rev Drug Discov,: 1-19 [Epub ahead of print]. [PMID:36781957]
  • Lies and Liabilities: Computational Assessment of High-Throughput Screening Hits to Identify Artifact Compounds.
     Alves V, Yasgar A, Wellnitz J, Bantukallu G, Rath M, Insilicall RB, Capuzzi S, Simeonov A, Muratov E, Zakharov A, Tropsha A. Lies and Liabilities: Computational Assessment of High-Throughput Screening Hits to Identify Artifact Compounds. (2023)  ChemRxiv, Preprint. DOI: 10.26434/chemrxiv-2023-r78sj
  • AI-enhanced protein design makes proteins that have never existed.
     Eisenstein M. AI-enhanced protein design makes proteins that have never existed. (2023)  Nat Biotechnol,: 1-3 [Epub ahead of print]. [PMID:36823357]
  • Pharmacological characterization of novel small molecule agonists and antagonists for the orphan receptor GPR139.
     Pallareti L, Rath TF, Trapkov B, Tsonkov T, Nielsen AT, Harpsøe K, Gentry PR, Bräuner-Osborne H, Gloriam DE, Foster SR. Pharmacological characterization of novel small molecule agonists and antagonists for the orphan receptor GPR139. (2023)  Eur J Pharmacol, 943: 175553 [Epub ahead of print]. [PMID:36736525]
  • Pharmacogenomics: current status and future perspectives.
     Pirmohamed M. Pharmacogenomics: current status and future perspectives. (2023)  Nat Rev Genet, [Epub ahead of print]. [PMID:36707729]
  • A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.
     Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, Böhringer S, Cambon-Thomsen A, Cecchin E, Cheung KC et al.. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. (2023)  Lancet, 401 (10374): 347-356. [PMID:36739136]

    • January 2023


  • Degrader-Antibody Conjugates: Emerging New Modality.
     Hong KB, An H. Degrader-Antibody Conjugates: Emerging New Modality. (2023)  J Med Chem, 66 (1): 140-148. [PMID:36580273]
  • Metabolites as signalling molecules.
     Baker SA, Rutter J. Metabolites as signalling molecules. (2023)  Nat Rev Mol Cell Biol, [Epub ahead of print]. [PMID:36635456]
  • Structures of the entire human opioid receptor family.
     Wang Y, Zhuang Y, DiBerto JF, Zhou XE, Schmitz GP, Yuan Q, Jain MK, Liu W, Melcher K, Jiang Y et al.. Structures of the entire human opioid receptor family. (2023)  Cell, 186 (2): 413-427.e17. [PMID:36638794]
  • Discovery of High-Affinity Small-Molecule Binders of the Epigenetic Reader YEATS4.
     Londregan AT, Aitmakhanova K, Bennett J, Byrnes LJ, Canterbury DP, Cheng X, Christott T, Clemens J, Coffey SB, Dias JM et al.. Discovery of High-Affinity Small-Molecule Binders of the Epigenetic Reader YEATS4. (2023)  J Med Chem, 66 (1): 460-472. [PMID:36562986]
  • Structural basis of odorant recognition by a human odorant receptor.
     Billesbølle CB, de March CA, van der Velden WJC, Ma N, Tewari, del Torrent JCL, Li L, Faust B, Vaidehi N, Matsunami H, Manglik A. Structural basis of odorant recognition by a human odorant receptor. (2023)  bioRxiv, Preprint. DOI: 10.1101/2022.12.20.520951
  • A proteome-wide atlas of drug mechanism of action.
     Mitchell DC, Kuljanin M, Li J, Van Vranken JG, Bulloch N, Schweppe DK, Huttlin EL, Gygi SP. A proteome-wide atlas of drug mechanism of action. (2023)  Nat Biotechnol, [Epub ahead of print]. [PMID:36593396]

    • December 2022


  • Pharos 2023: an integrated resource for the understudied human proteome.
     Kelleher KJ, Sheils TK, Mathias SL, Yang JJ, Metzger VT, Siramshetty VB, Nguyen DT, Jensen LJ, Vidović D, Schürer SC et al.. Pharos 2023: an integrated resource for the understudied human proteome. (2022)  Nucleic Acids Res, [Epub ahead of print]. DOI: 10.1093/nar/gkac1033
  • DrugCentral 2023 extends human clinical data and integrates veterinary drugs.
     Avram S, Wilson TB, Curpan R, Halip L, Borota A, Bora A, Bologa CG, Holmes J, Knockel J, Yang JJ et al.. DrugCentral 2023 extends human clinical data and integrates veterinary drugs. (2022)  Nucleic Acids Res, [Epub ahead of print]. [PMID:36484092]
  • Hot Topics: FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2

    Comments by the Guide to Pharmacology Curation Team, University of Edinburgh

    This manuscript reports on comprehensive and compelling experimental evidence and translational data from a retrospective review of clinical registries, which show that pharmacological inhibition of the farnesoid X receptor (FXR; using the FXR antagonist ursodeoxycholic acid/UDCA) could be a novel intervention for the prevention or treatment of COVID-19. The in vitro and in vivo studies show that FXR antagonism reduces ACE2 expression, which subsequently reduces SARS-CoV-2's ability to infect tissues including lung, liver and gastrointestinal tract.. Read the full article on our blog

    • November 2022


  • GPCRdb in 2023: state-specific structure models using AlphaFold2 and new ligand resources.
     Pándy-Szekeres G, Caroli J, Mamyrbekov A, Kermani AA, Keserű GM, Kooistra AJ, Gloriam DE. GPCRdb in 2023: state-specific structure models using AlphaFold2 and new ligand resources. (2022)  Nucleic Acids Res, [Epub ahead of print]. [PMID:36395823]
  • Colon tumour cell death causes mTOR dependence by paracrine P2X4 stimulation.
     Schmitt M, Ceteci F, Gupta J, Pesic M, Böttger TW, Nicolas AM, Kennel KB, Engel E, Schewe M, Callak Kirisözü A et al.. Colon tumour cell death causes mTOR dependence by paracrine P2X4 stimulation. (2022)  Nature, [Epub ahead of print]. [PMID:36385525]
  • Beyond PI3Ks: targeting phosphoinositide kinases in disease.
     Burke JE, Triscott J, Emerling BM, Hammond GRV. Beyond PI3Ks: targeting phosphoinositide kinases in disease. (2022)  Nat Rev Drug Discov,: 1-30 [Epub ahead of print]. [PMID:36376561]
  • Reclassifying plasmacytoid dendritic cells as innate lymphocytes.
     Ziegler-Heitbrock L, Ohteki T, Ginhoux F, Shortman K, Spits H. Reclassifying plasmacytoid dendritic cells as innate lymphocytes. (2022)  Nat Rev Immunol, [Epub ahead of print]. [PMID:36380022]
  • Structure determination of inactive-state GPCRs with a universal nanobody.
     Robertson MJ, Papasergi-Scott MM, He F, Seven AB, Meyerowitz JG, Panova O, Peroto MC, Che T, Skiniotis G. Structure determination of inactive-state GPCRs with a universal nanobody. (2022)  Nat Struct Mol Biol, [Epub ahead of print]. [PMID:36396979]

    • October 2022


  • Genenames.org: the HGNC resources in 2023.
     Seal RL, Braschi B, Gray K, Jones TEM, Tweedie S, Haim-Vilmovsky L, Bruford EA. Genenames.org: the HGNC resources in 2023. (2022)  Nucleic Acids Res, [Epub ahead of print]. [PMID:36243972]
  • Identification of proteomic landscape of drug-binding proteins in live cells by proximity-dependent target ID.
     Kwak C, Park C, Ko M, Im CY, Moon H, Park YH, Kim SY, Lee S, Kang MG, Kwon HJ et al.. Identification of proteomic landscape of drug-binding proteins in live cells by proximity-dependent target ID. (2022)  Cell Chem Biol, [Epub ahead of print]. [PMID:36272407]

    • September 2022


  • Visualizing classification of drugs used in psychotic disorders: A 'subway map' representing mechanisms, established classes and informal categories.
     Zhou C, Nutt DJ, Davies SJ. Visualizing classification of drugs used in psychotic disorders: A 'subway map' representing mechanisms, established classes and informal categories. (2022)  J Psychopharmacol,: 2698811221115758 [Epub ahead of print]. [PMID:36045588]

    • August 2022


  • Environmental pharmacology-Dosing the environment: IUPHAR review 36.
     Connolly CN, Alexander SPH, Davies JA, Spedding M. Environmental pharmacology-Dosing the environment: IUPHAR review 36. (2022)  Br J Pharmacol, [Epub ahead of print]. [PMID:35975296]
  • Future directions for the discovery of natural product-derived immunomodulating drugs: an IUPHAR positional review.
     Wainwright CL, Teixeira MM, Adelson DL, Buenz EJ, David B, Glaser KB, Harata-Lee Y, Howes MR, Izzo AA, Maffia P et al.. Future directions for the discovery of natural product-derived immunomodulating drugs: an IUPHAR positional review. (2022)  Pharmacol Res, 177: 106076. [PMID:35074524]
  • The past, present, and future of antibiotics.
     Cook MA, Wright GD. The past, present, and future of antibiotics. (2022)  Sci Transl Med, 14 (657): eabo7793. [PMID:35947678]
  • Mitochondrial remodeling and ischemic protection by G protein-coupled receptor 35 agonists.
     Wyant GA, Yu W, Doulamis IP, Nomoto RS, Saeed MY, Duignan T, McCully JD, Kaelin Jr WG. Mitochondrial remodeling and ischemic protection by G protein-coupled receptor 35 agonists. (2022)  Science, 377 (6606): 621-629. [PMID:35926043]
  • Isoforms of GPR35 have distinct extracellular N-termini that allosterically modify receptor-transducer coupling and mediate intracellular pathway bias.
     Schihada H, Klompstra TM, Humphrys LJ, Cervenka I, Dadvar S, Kolb P, Ruas JL, Schulte G. Isoforms of GPR35 have distinct extracellular N-termini that allosterically modify receptor-transducer coupling and mediate intracellular pathway bias. (2022)  J Biol Chem,: 102328 [Epub ahead of print]. [PMID:35933013]
  • Altiratinib blocks Toxoplasma gondii and Plasmodium falciparum development by selectively targeting a spliceosome kinase.
     Swale C, Bellini V, Bowler MW, Flore N, Brenier-Pinchart MP, Cannella D, Belmudes L, Mas C, Couté Y, Laurent F et al.. Altiratinib blocks Toxoplasma gondii and Plasmodium falciparum development by selectively targeting a spliceosome kinase. (2022)  Sci Transl Med, 14 (656): eabn3231. [PMID:35921477]

    • July 2022


  • The amyloid hypothesis on trial
    Lowe D. Faked Beta-Amyloid Data. What Does It Mean?.  In the Pipeline, https://www.science.org/content/blog-post/faked-beta-amyloid-data-what-does-it-mean
    Makin S. The amyloid hypothesis on trial. (2018)  Nature, 559 (7715): S4-S7. [PMID:30046080]
    Piller C. Blots on a field?. (2022)  Science, 377 (6604): 358-363. [PMID:35862524]
  • The role of free fatty acid receptor pathways in a selective regulation of TRPA1 and TRPV1 by resolvins in primary sensory neurons.
     Pyo HJ, An X, Cho H. The role of free fatty acid receptor pathways in a selective regulation of TRPA1 and TRPV1 by resolvins in primary sensory neurons. (2022)  J Cell Physiol, [Epub ahead of print]. [PMID:35802479]
  • Maresin 2 is an analgesic specialized pro-resolution lipid mediator in mice by inhibiting neutrophil and monocyte recruitment, nociceptor neuron TRPV1 and TRPA1 activation, and CGRP release.
     Fattori V, Zaninelli TH, Ferraz CR, Brasil-Silva L, Borghi SM, Cunha JM, Chichorro JG, Casagrande R, Verri Jr WA. Maresin 2 is an analgesic specialized pro-resolution lipid mediator in mice by inhibiting neutrophil and monocyte recruitment, nociceptor neuron TRPV1 and TRPA1 activation, and CGRP release. (2022)  Neuropharmacology, 216: 109189 [Epub ahead of print]. [PMID:35820471]
  • GPCRs steer Gi and Gs selectivity via TM5-TM6 switches as revealed by structures of serotonin receptors.
     Huang S, Xu P, Shen DD, Simon IA, Mao C, Tan Y, Zhang H, Harpsøe K, Li H, Zhang Y et al.. GPCRs steer Gi and Gs selectivity via TM5-TM6 switches as revealed by structures of serotonin receptors. (2022)  Mol Cell, [Epub ahead of print]. [PMID:35714614]
  • Hyaluronic acid-GPRC5C signalling promotes dormancy in haematopoietic stem cells.
     Zhang YW, Mess J, Aizarani N, Mishra P, Johnson C, Romero-Mulero MC, Rettkowski J, Schönberger K, Obier N, Jäcklein K et al.. Hyaluronic acid-GPRC5C signalling promotes dormancy in haematopoietic stem cells. (2022)  Nat Cell Biol, [Epub ahead of print]. DOI: 10.1038/s41556-022-00931-x [PMID:35725769]
  • GPR15L is an epithelial inflammation-derived pruritogen.
     Tseng PY, Hoon MA. GPR15L is an epithelial inflammation-derived pruritogen. (2022)  Sci Adv, 8 (24): eabm7342. DOI: 10.1126/sciadv.abm7342 [PMID:35704588]
  • TRPV1 SUMOylation suppresses itch by inhibiting TRPV1 interaction with H1 receptors.
     Gao Y, Ma R, Weng W, Zhang H, Wang Y, Guo R, Gu X, Yang Y, Yang F, Zhou A et al.. TRPV1 SUMOylation suppresses itch by inhibiting TRPV1 interaction with H1 receptors. (2022)  Cell Rep, 39 (11): 110972. [PMID:35705043]
  • An exercise-inducible metabolite that suppresses feeding and obesity.
     Li VL, He Y, Contrepois K, Liu H, Kim JT, Wiggenhorn AL, Tanzo JT, Tung AS, Lyu X, Zushin PH et al.. An exercise-inducible metabolite that suppresses feeding and obesity. (2022)  Nature, 606 (7915): 785-790. [PMID:35705806]

    • June 2022


  • The LOTUS initiative for open knowledge management in natural products research.
     Rutz A, Sorokina M, Galgonek J, Mietchen D, Willighagen E, Gaudry A, Graham JG, Stephan R, Page R, Vondrášek J et al.. The LOTUS initiative for open knowledge management in natural products research. (2022)  Elife, 11. [PMID:35616633]
  • A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor.
     Griffith DA, Edmonds DJ, Fortin JP, Kalgutkar AS, Kuzmiski JB, Loria PM, Saxena AR, Bagley SW, Buckeridge C, Curto JM et al.. A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor. (2022)  J Med Chem, 65 (12): 8208-8226. [PMID:35647711]
  • Tirzepatide Once Weekly for the Treatment of Obesity.
     Jastreboff AM, Aronne JL, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC et al.. Tirzepatide Once Weekly for the Treatment of Obesity. (2022)  New England Journal of Medicine, Epub ahead of print. DOI: 10.1056/NEJMoa2206038 [PMID:35658024]